Inhibition of mevalonate metabolism, silencing of the low-density lipoprotein receptor, and conjugation of cholesterol components with anticancer drugs have shown attractive effects on slowing cell growth and inducing apoptosis in various cancers [58–60]. This evidence concerns the gene LDLR and cancer.